Latest On EyeGate Pharmaceuticals, Inc (EYEG):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-05-01 05:45 EST | Dividend | A dividend of $0.15 has been announced on Apr 30, 2024. It will be paid May 7, 2024 with an ex-dividend date of May 1, 2024. | Neutral |  |
| 2024-05-01 05:45 EST | Dividend | A dividend of $0 has been announced on Nov 30, -0001. It will be paid May 7, 2024 with an ex-dividend date of May 1, 2024. | Neutral | |
| 2024-04-01 05:45 EST | Dividend | A dividend of $0.16 has been announced on Mar 28, 2024. It will be paid Apr 5, 2024 with an ex-dividend date of Apr 1, 2024. | Neutral | |
| 2021-08-13 13:02 EST | News | Eyegate Pharmaceuticals EPS beats by $0.07 | N/A | |
| 2021-08-11 00:34 EST | News | EyeGate under pressure on launch of $10.75M direct offering | N/A | |
| 2021-07-27 09:28 EST | News | EyeGate names Brian Strem CEO, proposes $7M Bayon deal | N/A | |
| 2021-03-26 08:36 EST | News | Eyegate Pharmaceuticals misses on revenue | N/A | |
| 2021-02-05 11:32 EST | Analyst Rating | The Analyst Target Price has increased from $14.83 to $15.25. | Buy | |
| 2021-01-06 20:17 EST | News | EyeGate Pharmaceuticals announces $8M private placement | N/A | |
| 2020-12-23 15:47 EST | Analyst Rating | The Analyst Target Price has increased from $11.5 to $14.83. | Buy | |
| 2020-12-21 08:09 EST | News | EyeGate surge in premarket as it acquires Panoptes Pharma for $4M | N/A | |
| 2020-12-01 11:56 EST | Analyst Rating | The Analyst Target Price has increased from $9.75 to $11.5. | Buy | |
| 2020-11-26 19:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 11:56 EST | Analyst Rating | The Analyst Target Price has decreased from $10.75 to $9.75. | Neutral | |
| 2020-11-12 03:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-11 03:50 EST | Earnings Estimate | An EPS average of -$0.46 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-10 13:05 EST | News | Eyegate Pharmaceuticals EPS misses by $0.02 | N/A | |
| 2020-11-07 15:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 12:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 08:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 15:10 EST | News | EyeGate Pharma rallies 67% on development path for conjunctivitis treatment | N/A | |
| 2020-08-09 00:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 17:58 EST | News | Eyegate Pharmaceuticals EPS beats by $0.05 | N/A | |
| 2020-08-07 08:41 EST | Earnings Estimate | An EPS average of -$0.43 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-08-06 20:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-24 00:40 EST | Analyst Rating | The Analyst Target Price has decreased from $12 to $10.75. | Neutral | |
| 2020-07-23 16:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-15 13:18 EST | News | EyeGate Pharma to proceed its lead product pivotal study in dry eye disease | N/A | |
| 2020-07-09 08:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-26 08:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 04:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-04 19:12 EST | Insider Trade | ARMISTICE CAPITAL, LLC has directly acquired 12,000 shares and currently holds 1,815,500 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | ARMISTICE CAPITAL, LLC has indirectly acquired of 0 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | ARMISTICE CAPITAL, LLC has indirectly acquired of 0 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | ARMISTICE CAPITAL, LLC has directly acquired 11,000 shares and currently holds 1,803,500 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | Brenda Mann has directly acquired 7,500 shares and currently holds 18,398 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | MICHAEL P. MANZO has directly acquired 7,500 shares and currently holds 18,421 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | Sarah Romano has directly acquired 10,000 shares and currently holds 26,742 shares. | Buy | |
| 2020-06-04 19:12 EST | Insider Trade | STEPHEN FROM has directly acquired 20,000 shares and currently holds 84,329 shares. | Buy | |
| 2020-06-02 08:38 EST | Analyst Rating | The Analyst Target Price has decreased from $90 to $12. | Neutral | |
| 2020-06-02 08:38 EST | Earnings Estimate | An EPS average of -$0.43 is estimated for the quarter ending on June 30, 2020. | N/A | |
| 2020-05-27 04:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-08 20:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 04:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-03 08:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-11 13:51 EST | News | EyeGate Pharma up 71% premarket on positive dry eye data | N/A | |
| 2020-04-03 00:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-22 00:37 EST | Financials | Company financials have been released. | Neutral | |
About EyeGate Pharmaceuticals, Inc (EYEG):
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
General
- Name EyeGate Pharmaceuticals, Inc
- Symbol EYEG
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Last Split Factor1:15
- Last Split Date2019-08-30
- Fiscal Year EndDecember
- IPO Date2015-07-31
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.eyegatepharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 7.3
- Price/Book (Most Recent Quarter) 6.69
- Enterprise Value Revenue 10.33
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.37
- Return on Assets -54%
- Return on Equity -150%
- Earnings Per Share -$2.27
- Revenue Per Share $0
- Gross Profit -2203357
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 39.37 million
- EBITDA -6660107
- Analyst Target Price $15.25
- Book Value Per Share $1.29
View More
Share Statistics
- Shares Outstanding 7.04 million
- Shares Float 2.26 million
- % Held by Insiders 396%
- % Held by Institutions 41.02%
- Shares Short 24346
- Shares Short Prior Month 37056
- Short Ratio 0.25
View More
Technicals
- Beta 1.16
- 52 Week High $7.85
- 52 Week Low $3.2
- 50 Day Moving Average 6.29
- 200 Day Moving Average 4.72
View More
Dividends
- Dividend Date 2019-08-30
- ExDividend Date N/A
- Dividend Yield 1.94%
View More
EyeGate Pharmaceuticals, Inc (EYEG) Dividend Calendar:
EYEG's last dividend payment was made to shareholders on August 30, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
EyeGate Pharmaceuticals, Inc (EYEG) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-09 | $N/A | -$0.44 | -$0.42 | -4.76% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.38 | -$0.43 | 11.63% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.43 | ||
| 2019-12-31 | 2020-03-04 | $N/A | -$0.76 | -$0.81 | 6.17% |
| 2019-09-30 | 2019-11-07 | $N/A | -$1.15 | -$0.75 | -53.33% |
| 2019-06-30 | 2019-08-08 | $N/A | -$0.60 | -$0.75 | 20% |
| 2019-03-31 | 2019-05-08 | $2.69 million | $0.15 | -$0.75 | 120% |
| 2018-12-31 | 2019-03-01 | $-314500 | -$0.75 | -$0.90 | 16.67% |
| 2018-09-30 | 2018-11-13 | $314500 | -$1.05 | -$1.13 | 6.67% |
| 2018-06-30 | 2018-08-03 | $242012 | -$1.05 | -$1.95 | 46.15% |
| 2018-03-31 | 2018-05-11 | $1.1 million | -$2.10 | -$3.53 | 40.43% |
| 2017-12-31 | 2018-03-02 | $332518 | -$2.25 | -$3.75 | 40% |
| 2017-09-30 | 2017-11-14 | $75000 | -$3.60 | -$3.30 | -9.09% |
| 2017-06-30 | 2017-08-04 | $148000 | -$4.20 | -$2.18 | -93.1% |
| 2017-03-31 | 2017-05-05 | $185000 | -$4.20 | -$5.25 | 20% |
| 2016-12-31 | 2017-02-23 | $160000 | -$5.70 | -$6.55 | 12.98% |
| 2016-09-30 | 2016-11-01 | $274000 | -$5.40 | -$6.68 | 19.1% |
| 2016-06-30 | 2016-08-10 | $235000 | -$6.90 | -$5.35 | -28.97% |
| 2016-03-31 | 2016-05-13 | $N/A | -$4.65 | -$4.55 | -2.2% |
| 2015-12-31 | 2016-03-29 | $N/A | -$3.60 | -$2.93 | -23.08% |
| 2015-09-30 | 2015-11-12 | $N/A | -$2.84 | ||
| 2015-06-30 | 2015-08-12 | $N/A | -$3.63 | ||
| 2015-03-31 | 2015-05-15 | $N/A | -$9.40 |
EyeGate Pharmaceuticals, Inc (EYEG) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 5.39 million | 2.41 million |
| Income Before Tax | N/A | N/A | N/A | -2.61 million | -3.43 million |
| Selling General Administrative | N/A | N/A | N/A | 1.12 million | 1.05 million |
| Gross Profit | N/A | N/A | N/A | 3.89 million | N/A |
| Ebit | N/A | N/A | N/A | -2.62 million | -3.45 million |
| Operating Income | N/A | N/A | N/A | -2.62 million | -3.45 million |
| Income Tax Expense | N/A | N/A | N/A | 95396 | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | -3.89 million | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | 10157 | 22887 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -2.7 million | -3.43 million |
| Net Income Applicable to Common Shares | -2.01 million | -1.72 million | -1.95 million | -2.7 million | -3.43 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -35799 | -59810 | -52843 | -857581 | 967828 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | 278190 | N/A | N/A | -1572 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 3.91 million | -15751 |
| Change to Operating Activities | 65045 | 61643 | -749554 | 119260 | 228897 |
| Change in Cash | N/A | N/A | N/A | 1.32 million | -2.01 million |
| Total Cash from Operating Activities | -1.74 million | -1.47 million | -2.4 million | -2.59 million | -2 million |
| Depreciation | N/A | N/A | N/A | 54742 | 53714 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -498687 | N/A | N/A | 11565 | -11565 |
| Change to Net Income | 187733 | 197051 | 305768 | 798808 | 179722 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 3.49 million | 3.66 million |
| Total Stockholder Equity | N/A | N/A | N/A | 6.62 million | 5.21 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A | 10.11 million | 8.87 million |
| Common Stock | 46268 | 46268 | 46268 | 40778 | 30365 |
| Other Current Assets | 61609 | N/A | N/A | 83926 | 125749 |
| Retained Earnings | -105.92 million | -103.92 million | -102.2 million | -100.25 million | -97.55 million |
| Other Liabilities | 2.08 million | 2.08 million | 2.08 million | 2.08 million | 1.48 million |
| Other Assets | 98034 | 4.02 million | 126019 | 114403 | 3.98 million |
| Cash | N/A | N/A | N/A | 3.78 million | 2.45 million |
| Total Current Liabilities | 930193 | N/A | N/A | 1.41 million | 2.18 million |
| Other Stockholder Equity | 122521 | 139631 | 139653 | 139465 | 137929 |
| Property, Plant & Equipment | 11253 | 13641 | 16029 | 16846 | 23514 |
| Total Current Assets | 3.5 million | N/A | N/A | 4.32 million | 3.11 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 323102 | 6.07 million | 3.67 million | 965454 | 3.46 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 59534 | N/A | N/A | 210289 | 1.07 million |
EyeGate Pharmaceuticals, Inc (EYEG) Chart:
EyeGate Pharmaceuticals, Inc (EYEG) News:
Below you will find a list of latest news for EyeGate Pharmaceuticals, Inc (EYEG) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
EyeGate Pharmaceuticals, Inc (EYEG) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
EyeGate Pharmaceuticals, Inc (EYEG) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1372514/000110465920077470/0001104659-20-077470-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm |
| 2020-01-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1372514/000110465920007189/0001104659-20-007189-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920011314/0001104659-20-011314-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920011324/0001104659-20-011324-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920011330/0001104659-20-011330-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920011342/0001104659-20-011342-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022838/0001104659-20-022838-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022841/0001104659-20-022841-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022843/0001104659-20-022843-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022844/0001104659-20-022844-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022845/0001104659-20-022845-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022846/0001104659-20-022846-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022847/0001104659-20-022847-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022848/0001104659-20-022848-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022849/0001104659-20-022849-index.htm |
| 2020-03-04 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1372514/000110465920029162/0001104659-20-029162-index.htm |
| 2020-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920031496/0001104659-20-031496-index.htm |
| 2020-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920031497/0001104659-20-031497-index.htm |
| 2020-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920031498/0001104659-20-031498-index.htm |
| 2020-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920031499/0001104659-20-031499-index.htm |
| 2020-03-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1372514/000110465920037762/0001104659-20-037762-index.htm |
| 2020-03-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1372514/000110465920040798/0001104659-20-040798-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920043261/0001104659-20-043261-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920043262/0001104659-20-043262-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920043263/0001104659-20-043263-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920043264/0001104659-20-043264-index.htm |
| 2020-04-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1372514/000110465920048224/0001104659-20-048224-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1372514/000110465920053380/0001104659-20-053380-index.htm |
| 2020-04-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1372514/000110465920053393/0001104659-20-053393-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1372514/000110465920057438/0001104659-20-057438-index.htm |
| 2020-05-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920057468/0001104659-20-057468-index.htm |
| 2020-05-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920057471/0001104659-20-057471-index.htm |
| 2020-05-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920057472/0001104659-20-057472-index.htm |
| 2020-05-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920057474/0001104659-20-057474-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1372514/000110465920067975/0001104659-20-067975-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920069822/0001104659-20-069822-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920069823/0001104659-20-069823-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920069824/0001104659-20-069824-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920069826/0001104659-20-069826-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1372514/000110465920077470/0001104659-20-077470-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920081219/0001104659-20-081219-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920081223/0001104659-20-081223-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920081225/0001104659-20-081225-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920081227/0001104659-20-081227-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920090917/0001104659-20-090917-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920090918/0001104659-20-090918-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920090919/0001104659-20-090919-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920090920/0001104659-20-090920-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1372514/000110465920091445/0001104659-20-091445-index.htm |
| 2020-08-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1372514/000110465920091458/0001104659-20-091458-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920102296/0001104659-20-102296-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920102298/0001104659-20-102298-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920102299/0001104659-20-102299-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920102300/0001104659-20-102300-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1372514/000110465920104579/0001104659-20-104579-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920112300/0001104659-20-112300-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920112301/0001104659-20-112301-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920112302/0001104659-20-112302-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920112303/0001104659-20-112303-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920120949/0001104659-20-120949-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920120953/0001104659-20-120953-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920120954/0001104659-20-120954-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1372514/000110465920120955/0001104659-20-120955-index.htm |
| 2020-08-05 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/1372514/000135445720000385/0001354457-20-000385-index.htm |
| 2020-02-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1372514/000139382520000038/0001393825-20-000038-index.htm |
EyeGate Pharmaceuticals, Inc (EYEG) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of EyeGate Pharmaceuticals, Inc (EYEG). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 396%Institutional Ownership: 4102%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-06 | ARMISTICE CAPITAL, LLC | Director | Buy | 0.00 | 1,803,500.00 | https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm | ||
| 2020-02-06 | ARMISTICE CAPITAL, LLC | Director | Buy | 11,000.00 | 6.18 | 67,980.00 | 1,803,500.00 | https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm |
| 2020-02-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 0.00 | 1,815,500.00 | https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm | ||
| 2020-02-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 12,000.00 | 6.04 | 72,480.00 | 1,815,500.00 | https://www.sec.gov/Archives/edgar/data/1372514/000091957420000888/0000919574-20-000888-index.htm |
| 2020-02-14 | Brenda Mann | VP of Research & Development | Buy | 7,500.00 | 18,398.00 | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022841/0001104659-20-022841-index.htm | ||
| 2020-02-14 | MICHAEL P. MANZO | VP of Engineering | Buy | 7,500.00 | 18,421.00 | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022843/0001104659-20-022843-index.htm | ||
| 2020-02-14 | Sarah Romano | Chief Financial Officer | Buy | 10,000.00 | 26,742.00 | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022848/0001104659-20-022848-index.htm | ||
| 2020-02-14 | STEPHEN FROM | President and CEO | Buy | 20,000.00 | 84,329.00 | https://www.sec.gov/Archives/edgar/data/1372514/000110465920022849/0001104659-20-022849-index.htm |